Medium materiality6/10
Jefferies Starts Iambic Therapeutics (IAM) at Buy
Why it may matterVerify against the original reporting
Bullish analyst initiation, tempered by the uncertainty inherent in relying on a single price target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Jefferies initiated coverage with a Buy rating and a $35 target, versus a posted price of $13.38. This is a substantial analyst-indicated upside, though it remains an analyst opinion.
- Jefferies: Buy; $35 target
- Posted price: $13.38
Key facts
- 01
Target: $35
- 02
Posted price: $13.38
- 03
Analyst firm: Jefferies
- 04
Analyst: Akash Tewari
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.